Disparities in universal prenatal screening for group B streptococcus--North Carolina, 2002-2003.
Group B streptococcus (GBS) is a leading cause of neonatal morbidity and mortality in the United States. Intrapartum antibiotics administered to women at risk for transmitting GBS to their newborns are effective in preventing perinatal GBS infection. In 2002, CDC, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists recommended universal prenatal screening for vaginal and rectal GBS colonization at 35-37 weeks' gestation. To examine prenatal GBS screening among pregnant women in North Carolina, CDC analyzed 2002 and 2003 data from the North Carolina Pregnancy Risk Assessment Monitoring System (PRAMS). The proportions of women reporting prenatal screening for GBS were similar in 2002 and 2003 (70% and 74%, respectively); however, for both years, women of Hispanic ethnicity and women who received prenatal care at a hospital or health department clinic were less likely to report prenatal screening for GBS. These findings underscore the need to increase GBS-related education and prevention activities targeted to these populations.
D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D007231:Infant, Newborn; D009657:North Carolina / Q000453:epidemiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis*; D011295:Prenatal Care / Q000706:statistics & numerical data*; D011296:Prenatal Diagnosis / Q000706:statistics & numerical data*; D013290:Streptococcal Infections / Q000175:diagnosis* / Q000517:prevention & control; D013292:Streptococcus agalactiae / Q000302:isolation & purification*